MeCo Diagnostics, CNIO publish study linking fibrosis and immunotherapy resistance in breast cancer

MeCo Diagnostics and the Spanish National Cancer Research Centre published a Journal of Clinical Investigation study on July 23, 2026 that ties osteopontin-driven mechanical conditioning to resistance in aggressive breast cancer. The findings strengthen the case for pairing antifibrotic therapy with immunotherapy and using the MeCo Score to identify patients most likely to benefit.

Why it matters: - The study links a fibrotic tumor environment to resistance against both antiangiogenic therapy and anti–PD-L1 immunotherapy in breast cancer models. - The findings support a combined antifibrotic and immunotherapy approach for patients with aggressive disease. - The MeCo Score is positioned as a predictive biomarker to help identify patients most likely to benefit from that integrated strategy.

What happened: - MeCo Diagnostics and long-time collaborators at the Spanish National Cancer Research Centre, or CNIO, published new research in the Journal of Clinical Investigation on July 23, 2026. - The paper is titled "Osteopontin mediates acquired resistance to hypoxia-inducing antiangiogenics and promotes anti–PD-L1 refractoriness in breast cancer models." - Dr. Miguel Quintela-Fandino, director of the Clinical Research Program at CNIO, led the study as senior author.

The details: - The research shows osteopontin plays a central role in mechanical conditioning, the process by which cancer cells adapt to a fibrotic extracellular matrix. - The MeCo Score is designed to measure that mechanical conditioning. - In a 2024 clinical study by the same collaboration, the antifibrotic drug nintedanib significantly reduced the risk of recurrence in patients with high MeCo Score tumors. - In a foundational 2021 translational study, MeCo Diagnostics showed osteopontin acts as an effector of "mechanical memory," an epigenetic phenomenon that locks in aggressive cancer cell behavior early and contributes to worse outcomes later. - The new study adds that osteopontin also drives resistance to immunotherapy in breast cancer models. - MeCo Diagnostics describes itself as a precision oncology company based in San Diego that develops predictive biomarker technology to leverage antifibrotic therapy for solid tumors. - More information is available on MeCo Diagnostics.

Between the lines: - The publication connects two previously separate ideas: fibrosis-targeted treatment and checkpoint immunotherapy resistance. - That overlap suggests tumor mechanics may be a broader driver of treatment failure than a single-therapy lens captures. - The MeCo Score could become more valuable if future studies confirm it can guide combination treatment decisions in real patients.

What's next: - Future clinical work will need to test whether antifibrotic therapy plus immunotherapy improves outcomes in patients selected by MeCo Score. - The collaboration's next step is likely to be validation of the biomarker and treatment strategy in broader breast cancer populations. - MeCo Diagnostics also maintains a company LinkedIn page for updates.